Savient sells gout med to Crealta

Share this article:

Pending court approval, Savient's orphan drug Krystexxa will join Crealta Pharmaceuticals' drug portfolio.

Savient announced the deal for its refractory chronic gout medication Wednesday.

The $120.4-million sale is part of a bankruptcy auction. The companies expect the court to weigh in on Friday.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions